TickerFacts.

QuidelOrtho Corp (QDEL): Revenue

Annual figures by period end, from SEC filings.

$2.73B
Year ended 2025-12-28
$2.67B
Trailing 12 months to 2026-06-28
-5.8%
3-year compound annual growth
+10.4%
5-year compound annual growth
$3.27B2021-01-03: $1.66B2022-01-02: $1.70B2023-01-01: $3.27B2023-12-31: $3.00B2024-12-29: $2.78B2025-12-28: $2.73B$2.73B
2021-01-03 Revenue (USD) 2025-12-28
Period endedRevenueChange YoYSource filing
2025-12-28$2.73B-1.9%2026-02-19, From 2024-12-30
2024-12-29$2.78B-7.2%2026-02-19, From 2024-01-01
2023-12-31$3.00B-8.2%2026-02-19, From 2023-01-02
2023-01-01, Fiscal 2022$3.27B+92.3%2025-02-27, From 2022-01-03
2022-01-02, Fiscal 2021$1.70B+2.2%2024-08-01, From 2021-01-04
2021-01-03, Fiscal 2020$1.66Bn/a2023-02-23, From 2019-12-30

Revenue at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
QuidelOrtho Corp (QDEL)2025-12-28$2.73B-1.9%
Idexx Laboratories Inc (IDXX)2025-12-31$4.30B+10.4%
Lantheus Holdings, Inc. (LNTH)2025-12-31$1.54B+0.5%
Neogen Corp (NEOG)2026-05-31$870.40M-2.7%
Myriad Genetics Inc (MYGN)2025-12-31$824.50M-1.6%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$67.67M+16.9%
Alpha Teknova, Inc. (TKNO)2025-12-31$40.52M+7.4%
Immucell Corp (ICCC)2025-12-31$27.64M+4.3%
Aspira Women's Health Inc. (AWHL)2025-12-31$9.22M+0.4%

Compare QDEL, IDXX, LNTH, NEOG side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗